RET and medullary thyroid gland carcinoma: On September 21, 2022, SLP (Retevmo®, Eli Lilly and Company) was granted accelerated approval by the Food and Drug Administration (FDA) in the United States for patients with either locally advanced or metastatic solid tumors involving metastatic RET fusion-positive NSCLCs along with RET fusion-positive thyroid cancers and RET-mutant medullary thyroid cancers that have proceeded on or after preceding systemic treatment or who have no suitable other treatment choices [6].